Selank was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences by Vladimir Khavinson and Tatiana V. Voronina, adapting the immune peptide tuftsin to study brain–immune signaling.

Each lot includes:

• Batch-specific COA with QR code verification
•  Purity: ≥98% verified by third-party HPLC
•  Identity: confirmed via mass spectrometry
• Endotoxin, sterility, and heavy-metal screening
• Full traceability from synthesis to shipment
• Stability Guaranteed: Lot tracking and stability testing supported

Not for human use. Not a drug. Not for diagnostic, therapeutic, or veterinary purposes.